Is it safe for an adult woman using the progestin‑only pill Slynd (drospirenone) to take naproxen, and does naproxen affect its contraceptive effectiveness or increase gastrointestinal bleeding risk?

Naproxen and Slynd Interaction

Naproxen can be taken with Slynd (drospirenone 4 mg progestin-only pill), but there is a theoretical risk of hyperkalemia that requires monitoring in at-risk patients, and naproxen does not reduce the contraceptive effectiveness of Slynd.

Contraceptive Effectiveness

• No drug interaction exists between naproxen and drospirenone that would compromise contraceptive efficacy 1.
• The Slynd FDA label specifically warns about potential hyperkalemia when combining drospirenone with NSAIDs (including naproxen), but this is a safety concern related to potassium levels, not contraceptive failure 1.
• Drospirenone maintains ovulation inhibition through its progestational effects, which are not metabolically affected by naproxen 2, 3.

Hyperkalemia Risk

The primary concern is elevated serum potassium, not contraceptive failure:

• Drospirenone is a spironolactone analogue with antimineralocorticoid properties that can increase serum potassium 1.
• NSAIDs like naproxen can also raise potassium levels, creating an additive risk when used together 1.
• This risk is most relevant in women with:
  • Renal impairment (Slynd is contraindicated in renal disease) 1
  • Concurrent use of other potassium-sparing medications (ACE inhibitors, ARBs, potassium supplements, aldosterone antagonists) 1
  • Baseline potassium in the upper reference range 1

Clinical approach: For healthy women with normal renal function taking Slynd, short-term naproxen use (e.g., for menstrual cramps or acute pain) poses minimal risk and requires no special monitoring 1. For chronic naproxen use or in women with risk factors, check baseline and periodic serum potassium levels 1.

Gastrointestinal Bleeding Risk

Naproxen carries inherent GI bleeding risk that is unrelated to Slynd use:

• Naproxen is associated with a 2-fold increased risk of serious GI bleeding compared to non-NSAID users 4.
• The one-year risk of serious GI bleeding from chronic NSAID use ranges from 1 in 2,100 in adults under 45 to 1 in 353 in older adults 4.
• Risk factors for NSAID-related GI bleeding include: age >65 years (2-3.5-fold increased risk), history of ulcers (2.5-4-fold increased risk), concurrent anticoagulant use (3-6-fold increased risk), and concurrent corticosteroid use (2-fold increased risk) 4.

Protective strategies if chronic naproxen is needed:

• Co-prescribe a proton pump inhibitor (PPI), which reduces bleeding ulcer risk by 75-85% in high-risk NSAID users 4.
• Consider celecoxib as an alternative, which has lower GI bleeding risk than naproxen (OR 1.16 vs 2.28 for ibuprofen, with naproxen likely similar or higher) 5, 6.
• Avoid naproxen in patients with prior ulcer bleeding; if NSAIDs are essential, celecoxib plus PPI is preferred over naproxen plus PPI 5.

Common Pitfalls

• Do not assume all NSAIDs are equivalent: Naproxen has higher GI bleeding risk than ibuprofen (relative risk 2.0) and substantially higher risk than celecoxib 5, 7, 6.
• Do not overlook the hyperkalemia warning: While rare in healthy women, the combination of drospirenone and naproxen can cause clinically significant hyperkalemia in susceptible patients 1.
• Do not confuse this with combined hormonal contraceptives: Unlike estrogen-containing pills, progestin-only pills like Slynd have no drug interactions that reduce contraceptive effectiveness with NSAIDs 4.

Special Considerations

• Naproxen may actually reduce menstrual bleeding in some women, which could be beneficial for those experiencing irregular bleeding on Slynd 8.
• For breastfeeding women, both naproxen and Slynd are considered safe 4, 1.
• Short-term naproxen use (≤10 days) for acute pain is generally safe in healthy Slynd users without additional monitoring 4, 1.